Lichen Planus Eruption Following Oxford-AstraZeneca COVID-19 Vaccine Administration: A Case Report and Review of Literature.

Hamzeh M Alrawashdeh, Omar Al-Habahbeh, Abdallah Y Naser, Hashem Abu Serhan, Omar Hamdan, Kanar Sweiss, Yousef Aldalameh
Author Information
  1. Hamzeh M Alrawashdeh: Department of Ophthalmology, Sharif Eye Centers, Irbid, JOR.
  2. Omar Al-Habahbeh: Department of Ophthalmology, Specialty Eye Hospital, Amman, JOR.
  3. Abdallah Y Naser: Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacoepidemiology, Isra University, Amman, JOR.
  4. Hashem Abu Serhan: Department of Ophthalmology, Islamic Hospital, Amman, JOR.
  5. Omar Hamdan: Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, CAN.
  6. Kanar Sweiss: Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy, Isra University, Amman, JOR.
  7. Yousef Aldalameh: Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy, Isra University, Amman, JOR.

Abstract

Lichen planus is an autoimmune inflammatory disease that can be associated with infections, drugs, and vaccines. Recently, it has been reported to occur following mRNA-based COVID-19 vaccines, particularly the Pfizer/BioNTech vaccine. We present the first reported case of lichen planus that developed after five days following the administration of the first dose of the Oxford-AstraZeneca vaccine in a 46-year-old healthy male. The skin eruption was purple, ill-defined, non-scaly, itchy, and distributed over his face, abdomen, back, and legs. The clinical appearance of the skin eruption and histopathology confirmed the diagnosis of lichen planus. The skin lesions were not responding well to topical steroid and oral antihistamine treatment. Thus, the patient was commenced on systemic hydroxychloroquine. The mechanism of lichen planus development following the administration of COVID-19 vaccines is unclear and needs more investigations and explanations. Healthcare providers should be aware of this possible adverse reaction following the administration of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. The histopathological features of lichen planus in our case are different from those found in the lichenoid drug eruption. This finding indicates different pathophysiology that needs further investigation.

Keywords

References

Front Immunol. 2021 Feb 24;12:640093 [PMID: 33717193]
J Am Acad Dermatol. 2021 Jul;85(1):46-55 [PMID: 33838206]
J Am Acad Dermatol. 2018 Nov;79(5):789-804 [PMID: 30318136]
Nat Microbiol. 2020 Oct;5(10):1185-1191 [PMID: 32908214]
Dermatol Ther. 2021 Nov;34(6):e15129 [PMID: 34533265]
Int J Dermatol. 2009 Jul;48(7):682-94 [PMID: 19570072]
Br J Dermatol. 2004 Dec;151(6):1172-81 [PMID: 15606512]
Int J Dermatol. 2007 Dec;46(12):1237-41 [PMID: 18173515]
J Cutan Pathol. 2014 Apr;41(4):347-52 [PMID: 24325780]
J Formos Med Assoc. 2022 Mar;121(3):723-724 [PMID: 34656402]
J Am Acad Dermatol. 2009 Jul;61(1):104-11 [PMID: 19539844]
Int J Dermatol. 2012 Oct;51(10):1199-205 [PMID: 22416968]
Clin Case Rep. 2021 Dec 07;9(12):e05092 [PMID: 34934493]
Dermatol Clin. 2021 Oct;39(4):653-673 [PMID: 34556254]
Infect Drug Resist. 2021 Aug 31;14:3459-3476 [PMID: 34511939]
Lancet. 2021 Apr 10;397(10282):1351-1362 [PMID: 33798499]
N Engl J Med. 2012 Feb 23;366(8):723-32 [PMID: 22356325]
Front Med (Lausanne). 2021 Sep 07;8:752443 [PMID: 34557507]
Viruses. 2020 May 10;12(5): [PMID: 32397688]
JAMA Dermatol. 2015 Mar;151(3):356 [PMID: 25760828]
J Eur Acad Dermatol Venereol. 2021 Sep;35(9):e548-e551 [PMID: 34021625]
Ned Tijdschr Geneeskd. 2001 Oct 6;145(40):1921-8 [PMID: 11675973]
Euro Surveill. 2021 Jul;26(28): [PMID: 34269175]
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e302-e303 [PMID: 32333823]
J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e729-e730 [PMID: 34236718]
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e414-e415 [PMID: 33724563]

Word Cloud

Similar Articles

Cited By